Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.69 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754917 | 0.82 | TRPV4 (1.00) | TRPV4IDO1SLC22A12CYP11B2AR | |
| SCHEMBL765561 | 0.78 | TRPV4 (0.64) | TRPV4MAOAMAOB | |
| SCHEMBL27280801 | 0.77 | TRPV4 (0.47) | TRPV4IDO1PGK1 | |
| SCHEMBL104941 | 0.76 | VCAM1 (0.52) | TRPV4VCAM1IDO1SLC22A12GRM4 | |
| SCHEMBL1966379 | 0.76 | TRPV4 (0.56) | TRPV4MAOAMAOB | |
| Fluoride SCHEMBL27571082 | 0.74 | VCAM1 (0.50) | TRPV4VCAM1IDO1SLC22A12GRM4 | |
| SCHEMBL3838602 | 0.74 | VCAM1 (0.50) | TRPV4VCAM1IDO1SLC22A12GRM4 | |
| SCHEMBL29898505 | 0.74 | VCAM1 (0.50) | TRPV4VCAM1IDO1SLC22A12GRM4 | |
| SCHEMBL16555923 | 0.73 | TRPV4 (0.69) | TRPV4GRM4CYP11B2AR | |
| SCHEMBL2668196 | 0.73 | TRPV4 (0.52) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790116-B | TRPV4 antagonists | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-20210299113-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| EP-3515888-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| WO-2018055526-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299113-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885VCAM1 2164/4885IDO1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.